Rosutin Tablet (Rosuvastatin): A Statin for Lipid Management and Cardiovascular Risk Reduction

Rosutin tablet contains Rosuvastatin, a potent medication belonging to the statin class. It is indicated for the management of various lipid disorders and for reducing the risk of cardiovascular events, primarily by lowering cholesterol levels.

How Rosutin Works (Pharmacology)

Rosuvastatin functions as a selective and competitive inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting step in cholesterol synthesis, converting 3-hydroxy-3-methyl glutaryl coenzyme A to mevalonate (a precursor of cholesterol).

Rosuvastatin achieves its lipid-modifying effects through two main mechanisms:

1. Increases LDL Receptors: It increases the number of hepatic LDL (low-density lipoprotein) receptors on the surface of liver cells. This enhances the uptake and breakdown (catabolism) of LDL cholesterol from the blood.
2. Inhibits VLDL Synthesis: It inhibits the liver's synthesis of VLDL (very low-density lipoprotein), which in turn reduces the total number of VLDL and LDL particles circulating in the bloodstream.

Key Indications & Benefits

Rosutin tablet is indicated for:

• Primary hyperlipidemia and mixed dyslipidemia: As an adjunct to diet to reduce elevated total-C (total cholesterol), LDL-C (bad cholesterol), ApoB (apolipoprotein B), non-HDL-C, and TG (triglyceride) levels, and to increase HDL-C (good cholesterol).
• Hypertriglyceridemia: As an adjunct to diet.
• Primary dysbetalipoproteinemia (Type III hyperlipoproteinemia): As an adjunct to diet.
• Homozygous familial hypercholesterolemia (HoFH): To reduce LDL-C, total-C, and ApoB.
• Slowing the progression of atherosclerosis: As part of a treatment strategy to lower total-C and LDL-C, as an adjunct to diet.
• Pediatric patients (10 to 17 years of age) with heterozygous familial hypercholesterolemia (HeFH): To reduce elevated total-C, LDL-C, and ApoB after an adequate trial of diet therapy has failed.
• Risk reduction of Myocardial Infarction (MI), stroke, and arterial revascularization procedures: In patients without clinically evident coronary heart disease (CHD) but with multiple risk factors.

Dosage & Administration

Dosage of Rosutin should be individualized based on the patient's condition and treatment goals. Always consult a registered physician for medication use.

• Heterozygous Familial Hypercholesterolemia (Pediatric Patients 10-17 years):
  • Usual dose range: 5-20 mg/day.
  • Maximum recommended dose: 20 mg/day.
  • Adjustments should be made at intervals of 4 weeks or more.
• Very High Cholesterol and High Risk of MI or Stroke: 40 mg once daily.
• Homozygous Familial Hypercholesterolemia: Recommended starting dose is 20 mg once daily.
• Dosage in Asian Patients: Initiation of therapy with 5 mg once daily should be considered.

Special Dosage Considerations:

• With Cyclosporine: Limit Rosuvastatin dose to 5 mg once daily.
• With Lopinavir/Ritonavir or Atazanavir/Ritonavir: Limit Rosuvastatin dose to 10 mg once daily.
• Concomitant Lipid-Lowering Therapy:
  • With Niacin or Fenofibrate: Consider reducing Rosuvastatin dosage due to enhanced risk of skeletal muscle effects.
  • With Gemfibrozil: Avoid combination. If co-administered, limit Rosuvastatin dose to 10 mg once daily.
• Severe Renal Impairment (ClCr < 30 mL/min/1.73 m² not on hemodialysis): Start at 5 mg once daily and do not exceed 10 mg once daily.

Important Considerations & Warnings

It is crucial to discuss your full medical history with your doctor before taking Rosutin.

Contraindications:

• Known hypersensitivity to product components.
• Liver disease, including unexplained persistent elevations in hepatic transaminase levels.
• Pregnant women and women who may become pregnant.
• Nursing mothers.

Side Effects:

Rosutin is generally well tolerated. The most frequent adverse events reported include:

• Headache
• Myalgia (muscle pain)
• Constipation
• Asthenia (weakness)
• Abdominal pain
• Nausea

Pregnancy & Lactation:

• Pregnancy: Rosuvastatin is contraindicated in pregnant women and women who may become pregnant. If pregnancy occurs during treatment, discontinue therapy immediately.
• Lactation: It is not known whether Rosuvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk. Rosuvastatin is contraindicated in nursing mothers.

Precautions & Warnings:

• Myopathy/Rhabdomyolysis Risk:
  • Prescribe with caution in patients with predisposing factors for myopathy (e.g., age >65 years, inadequately treated hypothyroidism, renal impairment).
  • Risk of myopathy may increase with concurrent administration of other lipid-lowering therapies (Fibrates or Niacin), Gemfibrozil, Cyclosporine, Lopinavir/Ritonavir, or Atazanavir/Ritonavir.
  • Discontinue Rosutin therapy if markedly elevated creatinine kinase (CK) levels occur or myopathy is diagnosed or suspected.
  • Temporarily withhold Rosutin therapy in any patient with an acute, serious condition suggestive of myopathy or predisposing to renal failure secondary to rhabdomyolysis (e.g., sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine, and electrolyte disorders, or uncontrolled seizures).
• Liver Enzyme Monitoring: It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semi-annually) thereafter.

Drug Interactions:

• Cyclosporine, Gemfibrozil, Lopinavir/Ritonavir, Atazanavir/Ritonavir: Increase Rosuvastatin exposure, requiring dose limitations (see Dosage & Administration section).
• Coumarin anticoagulants (e.g., Warfarin): Combination prolongs International Normalized Ratio (INR). INR should be stable before starting Rosutin and monitored frequently upon initiation or alteration of Rosutin therapy.
• Concomitant lipid-lowering therapies (Fibrates or Niacin): May increase the risk of skeletal muscle effects.

Overdose Effects

• There is no specific treatment in the event of overdose.
• Overdose should be managed symptomatically, and supportive measures instituted as required.
• Hemodialysis does not significantly enhance clearance of Rosutin.

Storage Conditions

Keep below 30°C temperature, protected from light & moisture. Keep out of the reach of children.